1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. SHP2
  4. SHP2 Inhibitor

SHP2 Inhibitor

SHP2 Inhibitors (67):

Cat. No. Product Name Effect Purity
  • HY-100388
    SHP099
    Inhibitor 99.80%
    SHP099 is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2D61Y, SHP2E69K, SHP2A72V, SHP2E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM). SHP099 inhibits RAS-ERK signaling and inhibits tumor growth.
  • HY-B0183
    Ellagic acid
    Inhibitor 99.23%
    Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.
  • HY-136173
    Batoprotafib
    Inhibitor 99.41%
    Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.
  • HY-116009
    RMC-4550
    Inhibitor 99.56%
    RMC-4550 is a potent, selective and allosteric inhibitor of SHP2, with an IC50 of 0.583 nM.
  • HY-141523
    Vociprotafib
    Inhibitor 99.47%
    Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice.
  • HY-161952
    JAB-3312
    Inhibitor
    JAB-3312 is an orally effective anticancer phosphatase SHP2 inhibitor (IC50: 1.9 nM) with anti-cancer activity. JAB-3312 has good tolerability and significantly induced tumor regression in a KYSE-520 mouse xenograft model.
  • HY-162476
    SHP2-IN-28
    Inhibitor
    SHP2-IN-28 (Compound 7188-0011) is an inhibitor of SHP2 (IC50=54.31 μM). SHP2-IN-28 exerts its inhibitory effect by binding to the variable site of SHP2 with high selectivity.
  • HY-169111
    SHP2-IN-32
    Inhibitor
    SHP2-IN-32 (compound C6) is an orally active, allosteric SHP2 inhibitor with an IC50 value of 0.13 nM. SHP2-IN-32 exhibits antitumor activity.
  • HY-100388A
    SHP099 monohydrochloride
    Inhibitor 99.92%
    SHP099 hydrochloride is a potent, selective and orally available SHP2 inhibitor with an IC50 of 70 nM.
  • HY-18756
    NSC-87877
    Inhibitor ≥99.0%
    NSC-87877 is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC50 values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).
  • HY-112368
    PHPS1
    Inhibitor 99.77%
    PHPS1 is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.
  • HY-144903
    Migoprotafib
    Inhibitor 98.06%
    Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor.
  • HY-137092
    IACS-13909
    Inhibitor 99.97%
    IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers.
  • HY-153740
    PF-07284892
    Inhibitor 99.37%
    PF-07284892 (ARRY-558) is a potent and orally active SHP2 inhibitor with an IC50 value of 21 nM. PF-07284892 decreases the expression of pERK.
  • HY-134885
    RMC-0331
    Inhibitor 98.96%
    RMC-0331 (RM-023) is a potent, selective and orally bioavailable SOS1 inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction.
  • HY-145162
    SHP2-D26
    Inhibitor
    SHP2-D26 is a first, potent and effective SHP2 degrader. SHP2-D26 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins. SHP2-D26 is also neddylation- and proteasome-dependent.
  • HY-114397
    SHP394
    Inhibitor 99.66%
    SHP394 is an orally active, selective and allosteric inhibitor of SHP2, with an IC50 of 23 nM.
  • HY-101964
    SPI-112
    Inhibitor
    SPI-112 is a potent, selective and competitive SHP2 (PTPN11) inhibitor with IC50s of 1 μM, 18.3 μM and 14.5 μM for SHP2, protein tyrosine phosphatase (PTP) and PTP1B, respectively.
  • HY-21336
    3-Azetidinemethanol hydrochloride
    Inhibitor ≥98.0%
    3-Azetidinemethanol hydrochloride, a medical intermediate, can be used in the synthesis of SHP2 inhibitor.
  • HY-115925
    SHP2-IN-9
    Inhibitor 98.68%
    SHP2-IN-9 is a specific SHP2 inhibitor (IC50 =1.174 μM) with enhanced blood–brain barrier penetration. SHP2-IN-9 shows 85-fold more selective for SHP2 than SHP1. SHP2-IN-9 inhibits SHP2-mediated cell signal transduction and cancer cell proliferation, and inhibits the growth of cervix cancer tumors and glioblastoma growth in vivo.